Achievement of ¥170 billion in sales, ¥20 billion in operating profit and other targets for fiscal 2025
First written in FY2017. 2 of 4 entries say "Softened", first in FY2020. Latest entry: FY2023.
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
- FY2023SoftenedAnnual report
「Under this plan, the performance targets for fiscal 2025, the final year, are revenue of ¥160 billion, operating profit of ¥12 billion, and ROE of 8.5%, ... Research expenses of ¥9 billion and capital investment of ¥50 billion are planned during the plan period.」
The previous fiscal 2025 targets of revenue of ¥170 billion, operating profit of ¥20 billion, and ROE of more than 12% have been changed to revenue of ¥160 billion, operating profit of ¥12 billion, and ROE of 8.5%. Research expenses of ¥9 billion and capital investment of ¥50 billion are planned. - FY2020SoftenedAnnual report
「Under this management plan, the Company aims to achieve fiscal 2022 targets of revenue of ¥120 billion, operating profit of ¥8 billion, and ROE of 8.5%.」
The previous fiscal 2025 targets of revenue of ¥170 billion, operating profit of ¥20 billion, and ROE of more than 12% have been changed to new fiscal 2022 targets of revenue of ¥120 billion, operating profit of ¥8 billion, and ROE of 8.5%. - FY2018Addition of fiscal 2020 interim targetsAnnual report
「As part of these initiatives, the company will invest approximately 4% of consolidated net sales in total R&D expenses and make investments of approximately ¥80 billion, aiming to achieve net sales of ¥170 billion, operating profit of ¥20 billion, an operating margin of 12%, and ROE of more than 12% as targets for the final year, FY2025.」
The fiscal 2025 targets were maintained, and interim targets were also presented for fiscal 2020, the midpoint of the plan: revenue of ¥130 billion, operating profit of ¥13 billion, an operating margin of 10%, and ROE of 10%. - FY2017First statedAnnual report
「As part of these initiatives, the company will invest approximately 4% of consolidated net sales in total R&D expenses and make investments of approximately ¥80 billion, aiming to achieve net sales of ¥170 billion, operating profit of ¥20 billion, an operating margin of 12%, and ROE of more than 12% as targets for the final year, FY2025.」
Using total research expenses and investment as means of investment, the Company has set fiscal 2025 targets of revenue of ¥170 billion, operating profit of ¥20 billion, an operating margin of 12%, and ROE of more than 12%.